Real-world Data Shows Immunotherapy After Melanoma Surgery Yields Survival Benefit
Sociodemographic factors may play a role in receiving immunotherapy PHILADELPHIA – Data derived from a large real-world database showed...
Search/Filter
Loading...
Personalized Cancer Vaccine Plus Atezolizumab Shows Clinical Activity in Patients With Advanced Solid Tumors
PHILADELPHIA – Treatment with the personalized cancer vaccine RO7198457 in combination with the PD-L1 inhibitor atezolizumab (Tecentriq) was well...
Survival May Be Lower for Hispanic Patients with Blood Cancers Who Live Near the United States/Mexico Border
PHILADELPHIA – In Texas, Hispanic patients with certain blood cancers had lower overall survival than non-Hispanic white patients, and...
AACR Virtual Annual Meeting I Draws More than 61,000 Registrants
Two-day Historic Online Scientific Meeting Featured 102 Oral Presentations and 126 Posters PHILADELPHIA – The American Association for Cancer...
Circulating Tumor DNA May Help Predict Recurrence in Patients with Early Triple-Negative Breast Cancer
Study also indicated that a lack of ctDNA may signal improved outcomes for patients SAN ANTONIO — The presence...
Residual Cancer Burden Can Predict Outcomes for Patients With Any Breast Cancer Type
SAN ANTONIO — A large meta-analysis of breast cancer patients showed that residual cancer burden after neoadjuvant chemotherapy is...
Oral Paclitaxel Yielded Better Outcomes Than Intravenous Paclitaxel for Metastatic Breast Cancer Patients in Phase III Trial
SAN ANTONIO — Metastatic breast cancer patients who received an oral formulation of the chemotherapy drug paclitaxel had better...
Long-term Follow-up Shows Estrogen Alone and Estrogen Plus Progestin Have Opposite Effects on Breast Cancer Incidence in Postmenopausal Women
Estrogen alone decreased, while adding progestin increased, breast cancer incidence SAN ANTONIO — Long-term follow-up results from two large,...
MINDACT Trial Data Reveal Certain Women With Luminal Breast Cancer May Be Undertreated With Tamoxifen Alone
SAN ANTONIO — Among women with hormone receptor (HR)-positive, HER2-negative breast cancer with a high clinical risk (determined by tumor...
Combining Atezolizumab with Neoadjuvant Chemotherapy Does Not Improve Pathologic Complete Response Rates for Patients with Triple-Negative Breast Cancer
SAN ANTONIO — The addition of the anti-PD-L1 immunotherapeutic atezolizumab (Tecentriq) to neoadjuvant chemotherapy for patients with triple-negative breast cancer (TNBC) did...